Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
143.97(c) 143.15(c) 138.36(c) 137.19(c) 137.11(c) Last
6 929 472 4 890 064 8 426 065 7 205 409 7 292 151 Volume
-0.87% -0.57% -3.35% -0.85% -0.06% Change
More quotes
Financials (USD)
Sales 2020 81 814 M - -
Net income 2020 15 967 M - -
Net Debt 2020 7 344 M - -
P/E ratio 2020 22,6x
Yield 2020 2,90%
Sales 2021 88 324 M - -
Net income 2021 18 332 M - -
Net cash position 2021 97,7 M - -
P/E ratio 2021 18,2x
Yield 2021 3,10%
Capitalization 361 B 361 B -
EV / Sales 2020 4,50x
EV / Sales 2021 4,09x
Nbr of Employees 132 200
Free-Float 84,3%
More Financials
Company
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... 
Sector
Pharmaceuticals
Calendar
11/11 | 12:45pmPresentation
More about the company
Notations Surperformance© of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
All news about JOHNSON & JOHNSON
03:01aKARO PHARMA : publishes third-quarter report 2020 and resolves on sale of own sh..
AQ
10/28Combined Market Cap of Five Largest MedTech Companies Surged by $40bn YoY
AQ
10/28JOHNSON & JOHNSON : Thinking about trading options or stock in Microsoft, First ..
PR
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
10/26JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
AQ
10/24AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23JOHNSON & JOHNSON : Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company S..
DJ
10/23JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
PU
10/23JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
DJ
10/22JOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2020
PR
10/22Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
DJ
10/20JOHNSON & JOHNSON : Janssen Demonstrates Strong Commitment to Research and Devel..
AQ
More news
News in other languages on JOHNSON & JOHNSON
10/27CORONAVIRUS : Pfizer n'est pas encore prêt à publier des résultats sur son vacci..
10/26J&J : demande à la FDA d'étendre l'utilisation du Xarelto
10/26Seconde vague
10/26EN DIRECT DES MARCHES : Europcar, Gecina, Sopra Steria, GL Events, Cellnex, SAP,..
10/23COVID-19 : le Canada annonce un accord pour un vaccin canadien
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 165,22 $
Last Close Price 137,11 $
Spread / Highest target 31,3%
Spread / Average Target 20,5%
Spread / Lowest Target 1,38%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518
NOVO NORDISK A/S9.93%154 639